Related Experiment Video
Updated: Apr 19, 2026

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
Two cases of cutaneous drug eruption associated with temozolomide therapy for glioblastoma
E Deluche1, S Leobon1, F Touraine2
1Department of Medical Oncology, University Hospital, Limoges, France.
Abstract:
Glioblastoma is the most common form of primary brain cancer. Its treatment involves surgery, radiotherapy, and chemotherapy with temozolomide (tmz), which is an oral alkylating agent. To the best of our knowledge, few dermatologic side effects of tmz have been described. We report two cases of cutaneous drug eruption caused by tmz during and after radiochemotherapy treatment. In the first case, all tests were negative, but the clinical history and the time of onset supported an allergy to tmz. In the second case, an allergy to tmz was proved by a positive lymphocyte activation test. In this context, our study is one of a very few trying to determine dermatologic side effects by applicable tests used in routine practice.
Related Concept Videos
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Drug Toxicity: Allergic Reactions
Drug toxicity: Idiosyncratic Reactions
Cytotoxic Edema: Pathophysiology
Tumor Immunotherapy
Allergic Drug Reactions

